Growth hormone, one of the essential hormones in the human body, plays a critical role not only in growth but also in regulating glucose, lipids and protein metabolism, as well as immune function. Currently, growth hormone is widely used to treat both pediatric and adult growth hormone deficiencies. It also shows significant potential in areas such as assisted reproduction and skin anti-aging.

Growth hormone is integral to key sectors like biopharmaceuticals, biotechnology and health management. As societal awareness of children's growth and general health continues to rise, the demand for growth hormones is expected to increase. According to Frost & Sullivan, the treatment rate for pediatric growth hormone deficiency (PGHD) in China was 4.8% in 2022 and is projected to reach 10.5% by 2030. The Chinese growth hormone market is expected to grow to CN¥35.8 billion by 2030, with a CAGR of 19.8% from 2018 to 2030.

As new indications are explored, including applications in assisted reproduction and anti-aging, the market potential for growth hormones in China will continue to expand.

With a "hundred-billion-level" growth potential, JHM aims to significantly improve patient adherence and reduce treatment costs through technological innovation. By strategically combining long-acting powder injections with conventional water-based injections, JHM plans to address the diverse needs of patients, benefiting a broader population.